ClinicalTrials.gg
Enrolling by invitationNCT07844668Updated Sep 28, 2026

Microbiome, Dietary and Quality of Life Analysis of People Living With CVID Treated With or Without Immunoglobulins.

An interventional study of Diet in CVID, SPAD and Antibody Deficiency, sponsored by Universitair Ziekenhuis Brussel. Enrolling by invitation at 2 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Universitair Ziekenhuis Brussel · Not applicable, Interventional, and Supportive care

How we know

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Our research group focusses on finding evidence-based diet strategies to overcome immune dysregulation either due to immune checkpoint inhibitors (ICI) or common variable immunodeficiency (CVID) (Figure 1). CVID is an inborn error of immunity, which is defined, among other factors, by a low level of immunoglobulins, resulting in an increased risk of infections, auto-immune/inflammatory diseases, and cancer.

The gut microbiome (GM) plays a crucial role in maintaining immune homeostasis and modulating the host's innate and adaptive immune responses. Modulation of the GM can be achieved by dietary interventions that have been demonstrated to change the composition of the GM within 2 weeks (Oliver et al., 2021). The intake of more than 30 different plant products (vegetables, fruits, seeds and grains) on a weekly basis is associated with a more diverse microbiome in healthy adults (McDonald et al., 2018). Although direct proof of a link between diet and functioning of the immune system is lacking, it is striking that in a retrospective study, melanoma patients treated with immune checkpoint inhibitors (ICI) had a better overall survival when they consumed enough fibers without taking probiotics (Spencer et al., 2021). Currently, we have included 54 of 60 foreseen patients receiving ICI in an interventional study (FORX-01 (NCT05832606)) at our centre, providing them weekly with 30 different plants to be integrated in their diet (funded by Delhaize and FWO). The aim is to measure if the interventional group develops less immune-related adverse events (= side effects of ICI) by changing their GM.

Similarly, we hypothesize that introducing a fiber-rich diet in patients with CVID will result in a more diverse GM leading to a decrease in autoimmune disorders and infections and as such lead to an improvement of quality of life. To challenge this hypothesis, we plan to organize a similar diet trial, called KNIVES. To prepare this study, we will first perform an observational study to describe the microbiome of people with CVID (DELICIOUS) followed at UZ Brussel.

02

Conditions studied

  • CVID
  • SPAD
  • Antibody Deficiency

Keywords

  • CVID
  • fiber-rich diet
  • spad
  • auto-immune
03

In context

Lead sponsor

Universitair Ziekenhuis Brussel is the lead sponsor of 375 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CVID diagnosis according to ESID criteria
  • 18y or older

Exclusion criteria

Exclusion Criteria:

  • start of therapeutic doses of antibiotics \< 30 days prior to inclusion
  • start of an immunomodulator \< 30 days prior to inclusion Patient excluded for the above reasons will be able to step in the study at a later timepoint (30 days after start of antibiotics of immunomodulators)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Other
    CVID participants of Observational cohort

    Participants assigned to this arm will follow a high-fiber dietary intervention according to the study protocol. Clinical outcomes, gastrointestinal symptoms, dietary intake, and biological samples will be collected throughout the study to assess the effects of the intervention.

    Other: Diet

Interventions

  • OtherDiet

    Participants receive individualized dietary counseling to increase their dietary fiber intake and follow a high-fiber diet according to the study protocol throughout the intervention period.

06

What researchers measure

Primary outcomes

  1. Primary outcomes

    To describe the gut microbiome of people living with CVID followed at UZ Brussel. To perform microbiome analysis through metagenomics (depending on availability, pricing, and emerging literature). To analyze one faecal sample of each participant at inclusion and additionally during infectious or autoinflammatory events. To assess microbiome diversity and composition, including: Alpha-diversity. Beta-diversity. Firmicutes/Bacteroidetes ratio (as a proximal marker for dysbiosis). Abundance of specific short-chain fatty acid-producing genera, including: Prevotella. Lactobacillaceae. Bifidobacteriaceae. Lachnospiraceae.

    Time frame: 1 year

Secondary outcomes

  1. Secondary outcome

    1. Dietary pattern assessment: Collection and analysis of 3-day food diaries at baseline according to Nubel, with focus on fiber intake. 2. CVID characteristics assessment: Classification of patients based on infectious complications, dysimmune complications, and IgA deficiency status. 3. Fatigue Severity Scale (Krupp et al., 1989). 4. CVID\_QoL questionnaire (Quinti et al., 2016). 5. EQ-5D questionnaire. 6. IBS Symptom Severity Scale. 7. Rome PI-IBS Questionnaire. 8. Rome IV Diagnostic Questionnaire for Adult Functional Gastrointestinal Disorders (R4DQ). 9. Gastrointestinal Symptom Rating Scale (GSRS).

    Time frame: 1 year

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Aug 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 28, 2026
StartActual
Aug 15, 2026
Primary completionEst.
Aug 2028
CompletionEst.
Sep 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07844668
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Aug 15, 2026
Primary completion
Aug 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Sep 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion